Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer

Published:2015-07-29 Issue:12 Volume:55 Page:1378-1385
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Laille Eric¹,Patel Manish²³,Jones Suzanne F.³,Burris Howard A.³⁴,Infante Jeffrey³⁴,Lemech Charlotte⁵,Liu Liangang¹,Arkenau Hendrik‐Tobias⁵⁶

Affiliation:

1. Celgene CorporationSummit, NJUSA

2. Florida Cancer SpecialistsSarasota, FLUSA

3. Sarah Cannon Research InstituteNashville, TNUSA

4. Tennessee Oncology, PLLCNashville, TNUSA

5. Sarah Cannon Research Institute UKLondonUK

6. University College LondonLondonUK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.560

Reference30 articles.

1. Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced byChromo-bacterium violaceumNo. 968, on Ha-rasTransformed NIH3T3 Cells

2. Romidepsin for peripheral T-cell lymphoma

3. Romidepsin: A Histone Deacetylase Inhibitor for Refractory Cutaneous T-Cell Lymphoma

4. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

5. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases;Furumai R;Cancer Res.,2002

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin;The Peripheral T‐Cell Lymphomas;2021-02-19

2. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study;Clinical Cancer Research;2020-08-14

3. A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors;Cancer;2019-04-23

4. Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin;AIDS;2018-07-31

5. Romidepsin (Istodax_® for intravenous injection 10 mg): pharmacokinetics, pharmacodynamics and clinical study outcome;Folia Pharmacologica Japonica;2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3